 <h1>Dabrafenib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of dabrafenib include:</b> squamous cell carcinoma, fever, and hyperglycemia. <b>Other side effects include:</b> keratoacanthoma.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dabrafenib: oral capsule</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dabrafenib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking dabrafenib:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding gums</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>coughing up blood</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>greatly decreased frequency of urination or amount of urine</li>
<li>headache</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>lump or growth on the skin</li>
<li>nausea</li>
<li>nosebleed</li>
<li>prolonged bleeding from cuts</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>skin blisters</li>
<li>skin rash</li>
<li>stomach pain</li>
<li>sweating</li>
<li>swelling of the feet or lower legs</li>
<li>tingling of the hands and feet</li>
<li>ulceration of the skin</li>
<li>unable to move</li>
<li>unexplained weight loss</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision or other change in vision</li>
<li>change in color vision</li>
<li>difficulty seeing at night</li>
<li>eye pain</li>
<li>increased sensitivity of the eyes to sunlight</li>
<li>redness of the eye</li>
<li>tearing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, loosening of the skin</li>
<li>chills</li>
<li>cough</li>
<li>diarrhea</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>red skin lesions, often with a purple center</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on lips</li>
<li>swollen, painful, or tender lymph glands in the neck, armpit, or groin</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dabrafenib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>difficulty having a bowel movement</li>
<li>fast heartbeat</li>
<li>hair loss or thinning of the hair</li>
<li>headache</li>
<li>indigestion</li>
<li>loss of appetite</li>
<li>muscle ache or stiffness</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>stuffy or runny nose</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dabrafenib: oral capsule</i></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperglycemia (71%), hypophosphatemia (38%), decreased appetite (29%), hyponatremia (57%)</p>
<p><b>Common</b> (1% to 10%): Dehydration<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased alkaline phosphatase (64%), increased AST (61%), increased ALT (38%)</p>
<p><b>Common</b> (1% to 10%): Increased gamma-glutamyltransferase, hyperbilirubinemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (55%), fatigue/asthenia/malaise (51%), chills (31%), edema (28%)</p>
<p><b>Common</b> (1% to 10%): Influenza-like illness, mucosal inflammation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (48%), anemia (46%), neutropenia (44%), lymphopenia (42%)</p>
<p><b>Common</b> (1% to 10%): Thrombocytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (45%), vomiting (33%), diarrhea (32%), constipation (13%), abdominal pain (11%)</p>
<p><b>Common</b> (1% to 10%): Dry mouth, stomatitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, gastrointestinal perforation, colitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hyperkeratosis (37%), rash (32%), dry skin (31%), alopecia (22%), palmar-plantar erythrodysesthesia syndrome (20%), pruritus, erythema</p>
<p><b>Common</b> (1% to 10%): Actinic keratosis, skin lesion, photosensitivity reaction, cellulitis, folliculitis, paronychia, pustular rash, dermatitis acneiform, night sweats, hyperhidrosis, panniculitis, skin fissures</p>
<p><b>Uncommon</b> (0.1% to 1%): Serious skin toxicity</p>
<p><b>Frequency not reported</b>: Bullous rash<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (32%), dizziness (11%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (27%), myalgia (15%), pain in extremity (14%), back pain (12%), muscle spasms</p>
<p><b>Common</b> (1% to 10%): Increased creatine phosphokinase</p>
<p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very common</b> (10% or more): Papilloma (27%)</p>
<p><b>Common</b> (1% to 10%): Cutaneous squamous cell carcinoma/keratoacanthoma/Bowen's disease, basal cell carcinoma, seborrheic keratosis, acrochordon</p>
<p><b>Uncommon</b> (0.1% to 1%): New primary melanoma<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hemorrhage (23%), hypertension (22%)</p>
<p><b>Common</b> (1% to 10%): Cardiomyopathy/decreased left ventricular ejection fraction, hypotension, lymphedema, bradycardia</p>
<p><b>Uncommon</b> (0.1% to 1%): QT prolongation, cardiac failure</p>
<p><b>Frequency not reported</b>: Myocarditis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (22%), dyspnea (20%), nasopharyngitis (12%)</p>
<p><b>Common</b> (1% to 10%): Interstitial lung disease/pneumonitis</p>
<p><b>Frequency not reported</b>: Respiratory distress<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (21%)</p>
<p><b>Common</b> (1% to 10%): Renal failure</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute renal failure, nephritis</p>
<p><b>Frequency not reported</b>: Interstitial nephritis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Uveitis, blurred vision, vision impairment</p>
<p><b>Uncommon</b> (0.1% to 1%): Chorioretinopathy, retinal detachment, periorbital edema<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline, Research Triangle Park, NC. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about dabrafenib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dabrafenib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Tafinlar</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Thyroid Cancer</li>
<li>Melanoma, Metastatic</li>
<li>Non-Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dabrafenib: oral capsule</i></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperglycemia (71%), hypophosphatemia (38%), decreased appetite (29%), hyponatremia (57%)</p><p><b>Common</b> (1% to 10%): Dehydration<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased alkaline phosphatase (64%), increased AST (61%), increased ALT (38%)</p><p><b>Common</b> (1% to 10%): Increased gamma-glutamyltransferase, hyperbilirubinemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (55%), fatigue/asthenia/malaise (51%), chills (31%), edema (28%)</p><p><b>Common</b> (1% to 10%): Influenza-like illness, mucosal inflammation<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (48%), anemia (46%), neutropenia (44%), lymphopenia (42%)</p><p><b>Common</b> (1% to 10%): Thrombocytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (45%), vomiting (33%), diarrhea (32%), constipation (13%), abdominal pain (11%)</p><p><b>Common</b> (1% to 10%): Dry mouth, stomatitis</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, gastrointestinal perforation, colitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hyperkeratosis (37%), rash (32%), dry skin (31%), alopecia (22%), palmar-plantar erythrodysesthesia syndrome (20%), pruritus, erythema</p><p><b>Common</b> (1% to 10%): Actinic keratosis, skin lesion, photosensitivity reaction, cellulitis, folliculitis, paronychia, pustular rash, dermatitis acneiform, night sweats, hyperhidrosis, panniculitis, skin fissures</p><p><b>Uncommon</b> (0.1% to 1%): Serious skin toxicity</p><p><b>Frequency not reported</b>: Bullous rash<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (32%), dizziness (11%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (27%), myalgia (15%), pain in extremity (14%), back pain (12%), muscle spasms</p><p><b>Common</b> (1% to 10%): Increased creatine phosphokinase</p><p><b>Uncommon</b> (0.1% to 1%): Rhabdomyolysis<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Very common</b> (10% or more): Papilloma (27%)</p><p><b>Common</b> (1% to 10%): Cutaneous squamous cell carcinoma/keratoacanthoma/Bowen's disease, basal cell carcinoma, seborrheic keratosis, acrochordon</p><p><b>Uncommon</b> (0.1% to 1%): New primary melanoma<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hemorrhage (23%), hypertension (22%)</p><p><b>Common</b> (1% to 10%): Cardiomyopathy/decreased left ventricular ejection fraction, hypotension, lymphedema, bradycardia</p><p><b>Uncommon</b> (0.1% to 1%): QT prolongation, cardiac failure</p><p><b>Frequency not reported</b>: Myocarditis<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (22%), dyspnea (20%), nasopharyngitis (12%)</p><p><b>Common</b> (1% to 10%): Interstitial lung disease/pneumonitis</p><p><b>Frequency not reported</b>: Respiratory distress<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased creatinine (21%)</p><p><b>Common</b> (1% to 10%): Renal failure</p><p><b>Uncommon</b> (0.1% to 1%): Acute renal failure, nephritis</p><p><b>Frequency not reported</b>: Interstitial nephritis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Uveitis, blurred vision, vision impairment</p><p><b>Uncommon</b> (0.1% to 1%): Chorioretinopathy, retinal detachment, periorbital edema<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline, Research Triangle Park, NC. </p><h2>More about dabrafenib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Dabrafenib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Thyroid Cancer</li>
<li>Melanoma, Metastatic</li>
<li>Non-Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>